drugset / Trial / NCT04924114
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
Timeline
- Start
- 2021-10-14
- Primary completion
- 2024-01-08
- Completion
- 2024-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-6194 | Unknown | — | Subcutaneous |